Information  X 
Enter a valid email address

Integumen PLC (SKIN)

  Print      Mail a friend

Thursday 25 April, 2019

Integumen PLC

Turner Pope Investor Evening

RNS Number : 0024X
Integumen PLC
25 April 2019

AIM share code: SKIN



Integumen PLC

("Integumen" or "Company")



Turner Pope Investor Evening

Integumen is pleased to announce that Gerry Brandon, the Company's CEO, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd, on Monday 13th May 2019. The event will be held in London, EC2 and will commence at 5pm.


If you want to find out how, in less than 9 months, new management have:


·      Cleared over £2m of short and long-term debts beginning with a cash deficit and no credit;

·      Eliminated multiple outstanding litigation disputes saving £495,000;

·      Increased revenues by 350% in the last 4 months of 2018;

·      Bought a company in April 2019 for £3m with growing revenues;

·      Placed £2.5m at 300% higher than the lowest share price, since taking over;

·      Turned a £1.5m market cap, close to bankruptcy, into a £15m market cap company; and,

·      Increased shareholder value by more than 400% from the lowest share price since taking over


And what all this means for the future of Integumen…


Then register your interest by emailing [email protected] or call on 0203 621 4124




Integumen plc

Gerard Brandon, CEO


+44 (0) 7340 055 643

SPARK Advisory Partners Limited

(Nominated Adviser)


Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited  (Broker)

Andy Thacker

+44 (0) 20 3621 4120


About Integumen:


Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.


The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t